More Phase 3 disappointment in Alzheimer’s disease
Alzheimer's underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.
The Phase 3 Alzheimer’s company few have heard of
Accera will soon deliver Phase 3 data on Alzheimer's disease, so why has nobody heard of them?
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.